H ealth care is expensive, and the inexorable rise in costs and our fractured health care system make managing resources ever more complicated. The Affordable Care Act of 2010 is expanding insurance coverage and is adding new mandates on accountable care in an attempt to control costs. 1 Prescription drug expenditures continue to increase-from about 10% of health care expenditures in 2008 ($234 billion), to nearly doubling of costs expected by around 2019. 2 The patient-centered medical home is now coming to the forefront of care, and while it is geared to improving health care quality and access in the long run, another goal is greater "shared decision making." 3, 4 Put together, new health care mandates and expanded population coverage, as well as rising drug costs and greater patient input into clinical decisions, will likely make pharmaceutical coverage decisions more complex, increasing the potential to pit patient and/or provider against payers.
Pharmaceuticals can provide substantial value to health, although some advances come at astronomical prices: Myozyme (alglucosidase alfa) for Pompe disease, at up to $300,000 annually is one example. 5 Emerging treatments for multiple sclerosis, such as Gilenya (fingolimod) at about $60,000 yearly, also increase costs. 6 Newer drugs for common diseases affect expenditures when patients are switched from cheaper alternatives. For example, atrial fibrillation is relatively common, and switching from warfarin to Pradaxa (dabigatran), at approxi- mately $3,000 annually, or to other newer oral anticoagulants, will push pharmacy expenditures upward for that condition. 7, 8 Various tactics have been advanced to promote more rational and optimal pharmaceutical use, including advocacy of conservative prescribing, leveraging formularies to enhance the quality of decision making for newer drugs, and focusing on goal-oriented patient care. [9] [10] [11] Some commentators have advocated changing the underlying behavior and attitudes of physicians, notably in cancer-related care. 12 More globally, health care payers rely on other means to control costs, such as prior authorization, utilization review, tiered copayments (i.e., cost sharing), therapeutic substitution of preferred (or generic) agents, and limiting coverage for selected agents. 13, 14 These latter approaches are not likely to disappear in the near future.
The decision-making complexity seen in pharmacy benefits management reflects many of the issues of dealing with expensive and limited health-associated resources. Our health care system is not contiguous, yielding conflicts among patients, providers, and payers, in turn reflecting differences between individual perspectives and payer and societal interests on coverage decisions. Fears about rationing, and limiting access to potentially valuable drugs, challenge rational discussions about these matters. 15 Often overlooked is the fact that managing pharmaceuticals, or any health care resource, at either the individual or population level, involves ethical (and other foundational) considerations. Indeed, such issues have been variably addressed in the past. As examples, Daniels et al. (2003) discussed developing an "ethical template for pharmacy benefits," allowing for a more robust framework on coverage and benefit decisions. 16 Simon et al. (2005) discussed 5 principles for "applying research evidence to formulary decisions." 17 Burton et al. (2001) focused on 6 ethical values to underpin pharmacy benefit management, so that at a policy level one could "manage these benefits in an ethically justifiable manner." 18 They focused on making key values explicit and discussing how polices can best "realize these values." Povar et al. (2004) reviewed a set of ethical principles or rules of engagement to guide managed care practices, principles that certainly overlap into pharmacy management, including the idea that clinicians-as well as health plans, purchasers, and the public-are all responsible for the "appropriate stewardship of health care resources." 19 More globally, the Academy of Managed Care Pharmacy has endorsed a series of statements and principles on managing medications within a formulary system, such as "basing formulary system decisions SUMMARY Decisions to control pharmaceutical costs can cause conflicts as to what medications are covered. Such conflicts have ethical implications, however implicit, and given this fact, an ethical framework can help address them. In the following commentary, we discuss the more traditional, individuallevel ethical considerations likely familiar to most clinicians. We, then, discuss population-level ethical constructs that clinicians may not as readily embrace. We also present a hypothetical cancer-care case to illustrate how imbalances in ethical foci between individual-and population-level constructs may lead to conflicts among health care actors and promote shifts in pharmaceutical decision making away from providers and toward payers, paradoxically reducing provider autonomy and hence patient autonomy. Finally, we propose a more comprehensive ethical framework to help converge individual, payer, and societal interests when making pharmaceutical use decisions. Pharmacists play a crucial role as pharmacy benefits managers and should be familiar with individual-and population-based ethical constructs.
and to use health care resources responsibly." 19 Stewardship and justice are of recognized importance in transplant medicine, for example, where there are strict rules concerning organ distribution and receipt; subverting those rules carries potentially severe penalties. 24 Antibiotic stewardship is another example of attempting to improve the shepherding of crucial resources, in that case by delaying the rise of antimicrobial resistance and preserving existing antibiotics' effectiveness.
Finally, parsimony prompts clinicians to practice mindfulness regarding costs, choosing-when practical and feasiblethe most economical among similarly effective treatments. As Emanuel (2012) stated regarding the new American College of Physicians Ethics Manual, "These positions on efficiency, parsimony, and cost effectiveness constitute an important shift, if not in ethics then in emphasis." 23 While these 3 population-level ethical constructs are of great import to population health and health care management, obviously clinicians emphasize the individual in care decisions, as stated in the American College of Physicians Ethics Manual: "The physician's first and primary duty is to the patient." 21 In practice, this statement means that most clinicians will not perceive that they have an overriding duty to enforce or oversee the more macro-or population-based concepts as they relate to patient care.
Conflicts Among and Limits of Ethical Values
When ethical values align, decisions are relatively easy, and most medical care likely falls into this alignment, at least when considering individual-level ethical issues. That is, decisions attempt to achieve the patient's best interests and honor autonomy and nonmaleficence. Conflicts arise when these principles do not coincide or when different parties perceive or weight them differently.
Providers in the United States heavily prioritize the precept of autonomy, expanding the notion in some instances to accommodate patient demands and/or acceding to patient authority. 22, 25 An example is the insistence by some patients, and, in many cases, agreement by clinicians, to prescribe an antibiotic for what diagnostically appears to be a viral infection. However, autonomy clearly is not absolute; patients cannot simply choose any treatment desired. Rather, autonomy involves the right to choose among reasonable alternatives, though in practice that may vary from provider to provider or patient to patient. In any case, limits to autonomy include contraindicated drugs or devices, physiologic futility, where there are legal boundaries on treatment (e.g., a demand for continued mechanical ventilation in the setting of brain death), or even requests for amputation of healthy limbs. 26 Thus, while patientcentered care may involve shared decision making, autonomy cannot and should not be unbounded or absolute.
Similarly, the principles of beneficence and nonmaleficence often depend on (variable) interpretation of potential benefits and harms of a clinical action (e.g., medication choice). For on cost factors only after the safety, efficacy and therapeutic need have been established" and "permitting financial incentives only when they promote cost management as part of the delivery of quality medical care." 20 While the above articles have outlined many general principles, and certainly provide important guidance on pharmaceutical coverage decisions, they have tended to focus on larger ethical or foundational boundaries and values within which individual decisions can be made. In that regard, we present a somewhat different approach by better addressing how ethical constructs can influence and guide coverage decisions at the point of care. We first discuss individual-level and populationlevel ethical constructs and how these can prompt divergent views and approaches. We then use a hypothetical cancer-care case to illustrate how differences in ethical foci may lead to conflicts and also to shifts in responsibility in decision making, paradoxically reducing autonomy of providers. Finally, we propose an ethical framework to help converge individual, payer, and societal interests when making pharmaceutical use decisions.
■■ Background The Ethical "Basics" in Medicine
Most clinicians know of basic individual-based medical ethics precepts: (a) autonomy, or the right to accept or refuse treatment(s); (b) beneficence, or acting for and/or representing a patient's best interests; and (c) nonmaleficence, more commonly known as "first, do no harm." Each of these, along with the fourth classic ethical principle of justice, discussed in the next section, forms a foundation for contemporary medical behaviors. 21 What is not evident is how these terms have evolved over time. Indeed, as Truog (2012) has noted, "Although the relationship between patients and doctors is often idealized in terms of universal and timeless principles, it has not been immune from the larger social and cultural forces surrounding it." 22 Ethical constructs, then, are dynamic and contextual.
Additional Ethical Constructs
In addition to the 3 individual-level ethical principles already mentioned, there are population-based ethical principles that govern, or should govern, clinicians' behaviors. These include justice, 21 stewardship, 19, 21 and parsimony (or parsimonious care). 21, 23 Justice focuses on fairness and equity in the distribution of health resources: For example, those who have little socioeconomic power should receive similar care to those who have more socioeconomic power. While the concept of justice does have individual-level implications, we classify justice as a population-based principle, since it implies relativism to other individuals.
Stewardship expresses the notion that health care providers must shepherd resources. As Povar et al. stated, "Clinicians have a responsibility to practice effective and efficient health care example, a prescriber who believes that combining a statin and fibrate is potentially beneficial for selected diabetics based on subanalyses of the ACCORD-Lipid trial will probably prescribe differently than one who believes that the combination provides no clinical benefit. 27 Simply put, different providers may come to different treatment decisions for the same or similar patients, despite acting consistently within an ethical framework.
Ethics, therefore, is a process, not an endpoint, and ethical analyses and decisions are inherently contextual. Thus, considering a more comprehensive ethical framework will help in understanding, and hopefully in resolving, differences in managing resources such as pharmaceuticals. But as more ethical constructs are added, the analysis becomes more complex. One problem is that population-based concepts of justice, parsimony, and stewardship are somewhat anathema to most clinicians focusing on the singular patients. Conversely, we would argue, health care organizations and payers do not have the context of the patient-provider interaction when making decisions.
Some might argue that justice, parsimony, and stewardship form the basis of rationing at the individual level. However, this objection ignores the complex interplay between populationbased health and individual health, whereby the health of the community can affect individuals (and vice versa), such as occurs in an epidemic. Rather, the 3 population-based concepts importantly augment the limited palette of autonomy, beneficence, and nonmaleficence to create a more appropriately nuanced schema through which ethical and practical problems can be understood.
■■ A Case Study: Collision of Values and Shifting Responsibilities
Conflicts are common among various participants in our health care system. As examples, discordance may occur because a patient wants a drug, but the provider declines to write the prescription, or because a patient (or prescriber) wants a drug, but the health care system or insurer declines coverage. These are simplified situations but are representative of many larger issues. The scenario below illustrates one such case.
Mr. J is a 76-year-old man with advanced non-small cell lung cancer, diagnosed 2 years ago. He has progressed through platinum-based chemotherapy and secondline oral maintenance chemotherapy. Brain and bone metastases have developed, and his functional status has declined substantially, to the point where he is now bedridden or in a chair for most of the day. However, he is lucid and has decision-making capacity, and he and his family want "everything" done, meaning more chemotherapy, if available. They are willing to risk any harm in order to prolong his life. In particular, they request that you prescribe a recently approved drug despite available studies suggesting only modest benefit (a median of 3 to 4 weeks) in patients with good performance status. The drug has the usual toxicity profile and is also extremely expensive.
One can now analyze this case using the ethical principles previously discussed. A focus on patient autonomy, used in the more liberal sense of acceding to patient authority, would favor offering the medication. The true roles of beneficence and nonmaleficence are somewhat more difficult to ascertain: The balance depends on how strongly a clinician believes that the drug might help the patient versus cause harm. That said, the likelihood of substantive benefit is quite low, and the risks of toxicity cannot be mitigated, so this balance would argue against prescribing the drug-though opinions will vary, and median benefit does not encompass outliers (however unlikely in this case).
The concept of justice, in which similar patients ought to be treated similarly, adds an important element. Certainly, it would be an untenable argument that the patient was justly entitled to the drug because most patients similar to him in other health care systems were getting it, unless of course that was indeed true. In such a case, justice would argue against a prescription. Stewardship and parsimony would further motivate against prescribing the agent.
So, the primary ethical principle arguing for the medication is autonomy. Realistically, the drug has little chance of benefit, and the provider should have probably explained that it is not an appropriate medication in this case. Yet, if the provider prescribes the drug, the payer or intermediary manager must then make a coverage decision. When providers push decision making onto payers that rightly should have occurred during the patient-physician interaction, there is an important change in dynamic, what we refer to as a "responsibility shift." This shift in the ethical framework is caused by moving the decision point to a third party. Such a change has both practical and ethical implications. The practical implication-one that is readily recognized-is that the provider/patient and payer may have a dysfunctional relationship if the drug is requested and not approved. The other implication, less obvious, is that there is a greater potential for nonalignment of individual-level and population-level ethical principles.
Of course, conflicts over pharmaceutical use are lessened when there is robust evidence of benefit and risks. But, when the evidence base is limited-a given in many areas such as in this case-then the chance of confrontation increases. To borrow one of Sir Isaac Newton's postulates, in such circumstances there will be an equal and opposite reaction by payers to offset patient (and provider) autonomy with more stringent adherence to justice, stewardship, and parsimony.
Thus, if clinicians are not mindful that their pharmaceutical use decisions have payer and societal consequences, then the oversight applied to clinicians will increase, paradoxically acting to reduce autonomous decision making. The challenge for providers, therefore, is to effectively advocate for individual patients while respecting societal standards. This challenge is easier when there is broad consensus, but new drugs and technologies disrupt consensus and precipitate uncertainty, leading to provider anxiety about doing the "right thing." As these situations arise, creating greater numbers of "responsibility shifts" to third parties, there are more chances for conflict.
■■ A Confluence of Interests: Melding Divergent Perspectives
If continued and rising conflict among various health care actors is predictable, along with shifts in decision-making responsibility, then a better framework is required for decision making, one that more explicitly encompasses and balances various ethical principles and reduces tensions among health care participants. Clinicians must, of course, continue to focus on quality-driven, evidence-based medicine and must outline, truthfully and realistically, available options to patients, even when options are limited or outcomes are uncomfortable to discuss. But, clinicians must also become more mindful of population-based ethics, especially as we move toward accountability for larger populations, that is, unless they want the principles of justice, stewardship, and parsimony foisted upon them. One way to think of this is to apply individual ethical principles to all patients collectively, with conscious regard for our professional obligations to society at large. 21 Conversely, insurers and payers must recognize that clinicians work within the patient-provider relationship or risk further alienating clinicians and patients and worsening future collaboration and cooperation.
In practical terms, though, there are many situations where use of a drug is questionable or where evidence is limited, though treatment is biologically plausible and/or a reasonable extension from the seminal study population. We propose that in selected situations a better balance of individual-and population-based ethics might be gained by using what we call outcomes-based coverage. This approach differs from the Center for Medicare and Medicaid Services' coverage with evidence development in that outcomes-based coverage does not primarily involve study participation or assessing whether patients fit into existing criteria for use. 28 Rather, in outcomes-based coverage, a drug is approved for a limited time for an individual patient, based on the expected duration needed to assess a prespecified and meaningful (and preferably objective) benefit. This agreement is between provider and insurer or payer. Continuance is then predicated on whether the outcome is met. Discontinuation occurs if significant harm or lack of efficacy occurs. To some degree, this situation occurs in routine clinical practice, because when something clearly does not work, it will more than likely be stopped. But, the method we propose is more systematic and, as noted, requires active collaboration between prescriber and payer and/or pharmacy manager.
This method is similar to an off-ventilator trial having timed periods with defined endpoints. Thus, in a situation similar to our scenario, perhaps in someone with less advanced disease, approval might be for an initial 3 months, with the agreement that if repeat imaging or clinical status indicates advancing disease, then chemotherapy is stopped. Continuation is thus predicated on on-going benefit. In terms of more global evidence development and/or data collection, as similar cases arise, data can be aggregated into more comprehensive information on benefits and harms, hopefully furthering the cause of (comparative) effectiveness studies and/or allowing for better future decision making for similar individuals.
While this approach cannot be universally applied, and will add some additional burden to providers and payers, it could help balance conflicts among clinicians, patients, and payers in treatment areas where there is limited evidence to make good clinical decisions. From a practical point of view, pharmacists will play a crucial link in the process and in implementing the system and lessening the burden on providers and payers, since they have key roles as pharmacy benefits managers. More globally, from an ethical viewpoint, the patient exercises autonomy, the provider advocacy, and the payer or manager, stewardship; this system emphasizes both individual and population components of ethical infrastructure in the face of medical uncertainty. Importantly, as Burton et al. noted, "Giving physicians and patients a voice in establishing and structuring controls on pharmaceutical use can restore some of the autonomy that such controls take away, albeit collectively rather than individually." 18 Finally, we would encourage health care organizations to track outcomes of individual coverage decisions, regardless of methods used to adjudicate those claims. While systematically reviewing outcomes for all coverage decisions would likely not be feasible in a large health care system, some assessment of those adjudications should be performed to make certain that the outcomes are consistent with the goals and mission of that organization.
■■ Conclusions
Managing expensive pharmaceuticals is becoming increasingly complex. Conflicts may arise between parties who focus differently on individual-level and population-based medical ethics. To find middle ground, clinicians will need to more strongly embrace the precepts of population-based ethical principles and beware of unfettered allegiance to patient autonomy or otherwise risk yielding part of their independent decision making to payers. Conversely, health care organizations and payers must continue to honor individual-level ethical principles and must understand the pressures that clinicians face in following the precepts of patient-centered care and shared decision making. Otherwise, payers risk further alienating clinicians and patients. Pharmacists will play a crucial role as pharmacy benefits managers and should be familiar with individual-and population-based ethical constructs. The principle of outcomes-based coverage may help develop a more collaborative and ethically robust framework for pharmaceutical coverage decisions.
